Drotrecogin alfa (activated): Treatment of septic shock

Drugs of the Future

Volumn 26, Issue 5, 2001, Pages 440-443

  Sorbera, L A ^a   Martin, L ^a   Castaner R M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FRACTALKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LY 203638; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; MORTALITY; NONHUMAN; SEPTIC SHOCK; SURVIVAL RATE; THROMBOSIS;

EID: 0034912180     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.05.620122     Document Type: Article

References (38)

1. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
2. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units
3. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
4. Adjunctive therapy for septic shock: A review of experimental approaches
5. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study
6. Thrombin signalling and protease-activated receptors
7. Regulation of blood coagulation
8. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
9. Trans-activated expression of fully γ-carboxylated recombinant human protein C, an antithrombotic factor
10. Characterization and novel purification of recombinant human protein C from three mammalian cell lines
11. Transcript profiling of human endothelial cells defines novel mechanisms by which recombinant human activated protein C regulates pro-inflammatory pathways
12. Comparison of activated protein C/protein S mediated inactivation of human factor VIII and factor V
13. The anticoagulant and antithrombotic activities of recombinant human activated protein C - Apparent lack of species specificity
14. Activated recombinant human protein C does not attenuate recruitment of neutrophils in rat models of acute inflammation
15. Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis
16. Evaluation of activated protein C on canine infarct size in a nonthrombotic model of myocardial reperfusion injury
17. Preclinical pharmacology of activated protein C
18. An optimized immunocaptureamidolytic assay for the quantification of LY203638 (activated protein C)
19. Recombinant human activated protein C (rhAPC) improves coagulation abnormalities, morbidity and 28 day mortality in patients with severe sepsis
20. Recombinant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28 day survival in patients with severe sepsis
21. The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis
22. Efficacy and safety of recombinant human activated protein C for severe sepsis
23. Effect of patient baseline characteristics on the mortality reduction associated with recombinant human activated protein C (rhAPC) in patients with severe sepsis
24. Effect of baseline protein C, antithrombin and IL-6 levels on the mortality reduction associated with recombinant human activated protein C in patients with severe sepsis
25. Effect of age on mortality reduction associated with recombinant human activated protein C in patients with severe sepsis
26. Attenuation of sepsis-induced coagulation and inflammation by recombinant human activated protein C
27. The effect of recombinant human activated protein C on hospital costs and resource use in severe sepsis
28. Lilly highlights significant events over last three months: Selected late-stage compounds updated
29. Drotrecogin alfa (activated) granted FDA priority review for severe sepsis